Cardiovascular disease (CVD) remains the primary cause of morbidity and mortality worldwide. The abnormal proliferation of vascular smooth muscle cells (VSMCs) is a key event in the pathogenesis of CVD. The functional and phenotypic changes in vascular cells are mediated by complex signaling cascades that initiate and control genetic reprogramming. Many studies have demonstrated that signal transducer and activator of transcription 3 (STAT3) regulates a diverse array of functions relevant to atherosclerosis.
Methods
In this review, we summarize the studies on the STAT3-mediated proliferation of VSMCs and subsequent CVDs such as hypertension, atherosclerosis, stroke, coronary artery disease, and myocardial infarction. Furthermore, we describe the general background of STAT3, its structure, function and regulation as well as the STAT3 signaling pathway. Finally, we highlight some potential issues and propose some solutions to these issues.
Results and conclusions: STAT3 activation promotes the proliferation of VSMCs by regulating the transcription of genes. Studying the mechanism of VSMC proliferation induced by the STAT3 pathway is valuable for finding therapeutic targets for CVD.
Gregory AR, Degu A, Kalkidan HA, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet2018; 392: 1736–1788.
2.
Kapustin AN and Shanahan CM.Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation. J Physiol2016;
594: 2905–2914.
3.
Owens GK.Regulation of differentiation of vascular smooth muscle cells. Physiol Rev1995;
75: 487–517.
4.
Owens GK, Kumar MS and Wamhoff BR.
Molecular regulation of vascular smooth muscle cell differentiation in development and diseae. Physiol Rev2004;
84: 767–801.
5.
Chistiakov DA, Orekhov AN and Bobryshev YV.
Vascular smooth muscle cell in atherosclerosis. Acta Physiol2015;
214: 33–50.
6.
Fang YC and Yeh CH.
Role of microRNAs in Vascular Remodeling. Curr Mol Med2015;
15: 684–696.
7.
YuHLeeHHerrmannA, et al.
Revisiting STAT3 signalling in cancer: new and unexpected biological functions.Nat Rev Cancer2014;
14: 736–746.
8.
DutzmannJDanielJMBauersachsJ, et al.
Emerging translational approaches to target STAT3 signalling and its impact on vascular disease.Cardiovasc Res2015;
106: 365–374.
9.
Dzau VJ, Braun-Dullaeus RC and Sedding DG.
Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med2002;
8: 1249–1256.
10.
Sherr CJ and Roberts JM.
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev1999;
13: 1501–1512.
11.
Lee JJ, Zhang WY, Yi Het al.
Anti-proliferative actions of 2-decylamino-5,8-dimethoxy-1,4-naphthoquinone in vascular smooth muscle cells. Biochem Biophys Res Commun2011;
411: 213–218.
12.
Bicknell KA, Surry EL and Brooks G.
Targeting the cell cycle machinery for the treatment of cardiovascular disease. J Pharm Pharmacol2003;
55: 571–591.
13.
LevyDEDarnellJEJr.Stats: transcriptional control and biological impact.Nat Rev Mol Cell Biol2002;
3: 651–662.
14.
O’Shea JJ, Gadina M and Schreiber RD.
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell2002;
109Suppl: S121–131.
15.
LimCPCaoX.Structure, function, and regulation of STAT proteins.Mol Biosyst2006;
2: 536–550.
16.
Schaefer TS, Sanders LK, Park OKet al.
Functional differences between Stat3alpha and Stat3beta. Mol Cellul Biol1997;
17: 5307–5316.
17.
Maritano D, Sugrue ML, Tininini Set al.
The STAT3 isoforms alpha and beta have unique and specific functions.Nat Immunol2004;
5: 401–409.
18.
Park OK, Schaefer LK, Wang Wet al.
Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms. J Biol Chem2000;
275: 32244–32249.
19.
Yang J, Chatterjee-Kishore M, Staugaitis SMet al.
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res2005;
65: 939–947.
20.
Tierney MT, Aydogdu T, Sala Det al.
STAT3 signaling controls satellite cell expansion and skeletal muscle repair. Nat Med2014;
20: 1182–1186.
21.
Hirano T, Ishihara K and Hibi M.
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene2000;
19: 2548–2556.
22.
Fukada T, Ohtani T, Yoshida Y, et al.STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J1998;
17: 6670–6677.
23.
MatesJMSeguraJAAlonsoFJ, et al.
Oxidative stress in apoptosis and cancer: an update.Arch Toxicol2012;
86: 1649–1665.
24.
Griendling KK and Ushio-Fukai M.
Redox control of vascular smooth muscle proliferation. J Lab Clin Med1998;
132: 9–15.
25.
SuBMitraSGreggH, et al.
Redox regulation of vascular smooth muscle cell differentiation.Circ Res2001;
89: 39–46.
26.
Seki Y, Kai H, Shibata R,et al.
Role of the JAK/STAT pathway in rat carotid artery remodeling after vascular injury. Circ Res2000;
87: 12–18.
27.
Yoshimura A, Naka T and Kubo M.
SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol2007;
7: 454–465.
28.
Goetze S, Kintscher U, Kaneshiro Ket al.
TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Atherosclerosis2001;
159: 93–101.
29.
Jovinge S, Hultgardh-Nilsson A, Regnstrom J,et al.
Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. Arterioscler Thromb Vasc Biol1997;
17: 490–497.
30.
Zinkevich NS and Gutterman DD.
ROS-induced ROS release in vascular biology: redox-redox signaling. Am J Physiol Heart Circ Physiol2011;
301: H647–653.
31.
Satoh K, Nigro P and Berk BC.
Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A.Antioxidant Redox Signal2010;
12: 675–682.
32.
Crowley SD, Gurley SB, Herrera MJet al.
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA2006;
103: 17985–17990.
33.
Garrido AM and Griendling KK.
NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol2009;
302: 148–158.
34.
AlvarezSESeguinLRVillarrealRS, et al.
Involvement of c-Src tyrosine kinase in SHP-1 phosphatase activation by Ang II AT2 receptors in rat fetal tissues.J Cell Biochem2008;
105: 703–711.
35.
Tsai CT, Lai LP, Kuo KTet al.
Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling.Circulation2008;
117: 344–355.
36.
Zheng L, Jia X, Zhang Cet al.
Angiotensin II in atrial structural remodeling: the role of Ang II/JAK/STAT3 signaling pathway. Am J Transl Res2015;
7: 1021–1031.
37.
Sun HJ, Ren XS, Xiong XQet al.
NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension.Cell Death Dis2017;
8: e3074.
38.
Hao PP, Chen YG, Liu YPet al.
Association of plasma angiotensin-(1-7) level and left ventricular function in patients with type 2 diabetes mellitus. PloS One2013;
8: e62788.
39.
Ben P, Hu M, Wu Het al.
L-theanine down-regulates the JAK/STAT3 pathway to attenuate the proliferation and migration of vascular smooth muscle cells induced by angiotensin II. Biol Pharmaceut Bull2018;
41: 1678–1684.
40.
ChenJZhangWXuQ, et al.
Ang-(1-7) protects HUVECs from high glucose-induced injury and inflammation via inhibition of the JAK2/STAT3 pathway.Int J Mol Med2018;
41: 2865–2878.
41.
Hahn CG and Friedman E.
Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disorder1999;
1: 81–86.
42.
Jacobson PB, Kuchera SL, Metz Aet al.
Anti-inflammatory properties of Gö 6850: a selective inhibitor of protein kinase C. J Pharmacol Exp Therapeut1995;
275: 995–1002.
43.
Hsieh HL, Lin CC, Shih RHet al.
NADPH oxidase-mediated redox signal contributes to lipoteichoic acid-induced MMP-9 upregulation in brain astrocytes. J Neuroinflamm2012;
9: 110.
44.
InoguchiTSontaTTsubouchiH, et al.
Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase.J Am Soc Nephrol2003;
14: S227–232.
45.
LeeITLinCCWangCH, et al.
ATP stimulates PGE(2)/cyclin D1-dependent VSMCs proliferation via STAT3 activation: role of PKCs-dependent NADPH oxidase/ROS generation.Biochem Pharmacol2013;
85: 954–964.
46.
Lee HK, Park DW, Bae JHet al.
RGS2 is a negative regulator of STAT3-mediated Nox1 expression. Cell Signal2012;
24: 803–809.
47.
Abedi H and Zachary I.
Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc Res1995;
30: 544–556.
48.
Kawai-Kowase K and Owens GK.
Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Am J Physiol Cell Physiol2007;
292: C59–69.
49.
Simeone-Penney MC, Severgnini M, Rozo Let al.
PDGF-induced human airway smooth muscle cell proliferation requires STAT3 and the small GTPase Rac1. Am J Physiol Lung Cell Mol Physiol2008;
294: L698–704.
50.
Park HS, Quan KT, Han JHet al.
Rubiarbonone C inhibits platelet-derived growth factor-induced proliferation and migration of vascular smooth muscle cells through the focal adhesion kinase, MAPK and STAT3 Tyr signalling pathways.Br J Pharmacol2017;
174: 4140–4154.
51.
PanJLiKHuangW, et al.
MiR-137 inhibited cell proliferation and migration of vascular smooth muscle cells via targeting IGFBP-5 and modulating the mTOR/STAT3 signaling.PLoS One2017;
12: e0186245.
52.
Guo X, Li D, Chen Met al.
miRNA-145 inhibits VSMC proliferation by targeting CD40.Sci Rep2016;
6: 35302.
53.
Bi R, Ding F, He Yet al.
miR-503 inhibits platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration through targeting the insulin receptor.Biomed Pharmacother2016;
84: 1711–1716.
54.
Wang P, Xu J, Hou Zet al.
miRNA-34a promotes proliferation of human pulmonary artery smooth muscle cells by targeting PDGFRA. Cell Prolif2016;
49: 484–493.
55.
Li TJ, Chen YL, Gua CJet al.
MicroRNA 181b promotes vascular smooth muscle cells proliferation through activation of PI3K and MAPK pathways. Int J Clin Exp Pathol2015;
8: 10375–10384.
56.
Watanabe S, Mu W, Kahn Aet al.
Role of JAK/STAT pathway in IL-6-induced activation of vascular smooth muscle cells.Am J Nephrol2004;
24: 387–392.
57.
Wang D, Liu Z, Li Qet al.
An essential role for gp130 in neointima formation following arterial injury. Circ Res2007;
100: 807–816.
58.
Mitsumata M, Gamou S, Shimizu Net al.
Response of atherosclerotic intimal smooth muscle cells to epidermal growth factor in vitro. Arterioscler Thromb1994;
14: 1364–1371.
59.
Lee KS, Park JH, Lee Set al.
HB-EGF induces delayed STAT3 activation via NF-kappaB mediated IL-6 secretion in vascular smooth muscle cell. Biochim Biophys Acta2007;
1773: 1637–1644.
60.
IkedaU IMOoharaT, et al.
Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner.Am J Physiol1991;
260(5 Pt 2):H1713–7.
61.
Cuneo AA, Herrick D and Autieri MV.
IL-19 reduces VSMC activation by regulation of mRNA regulatory factor HuR and reduction of mRNA stability. J Mol Cell Cardiol2010;
49: 647–654.
62.
Tian Y, Sommerville LJ, Cuneo Aet al.
Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of intimal hyperplasia. Am J Pathol2008;
173: 901–909.
63.
XiangSLiuJDongN, et al.
Suppressor of cytokine signaling 3 is a negative regulator for neointimal hyperplasia of vein graft stenosis.J Vasc Res2014;
51: 132–143.
64.
Gabunia K, Ellison SP, Singh Het al.
Interleukin-19 (IL-19) induces heme oxygenase-1 (HO-1) expression and decreases reactive oxygen species in human vascular smooth muscle cells. J Biol Chem2012;
287: 2477–2484.
65.
Tulis DA, Durante W, Liu Xet al.
Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation2001;
104: 2710–2715.
66.
Oh-I S, Shimizu H, Satoh Tet al.
Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature2006;
443: 709–712.
67.
Lu QB, Wang HP, Tang ZHet al.
Nesfatin-1 functions as a switch for phenotype transformation and proliferation of VSMCs in hypertensive vascular remodeling.Biochim Biophys Acta Mol Basis Dis2018;
1864: 2154–2168.
68.
Qi YX, Yao QP, Huang K,et al.
Nuclear envelope proteins modulate proliferation of vascular smooth muscle cells during cyclic stretch application.Proc Natl Acad Sci USA2016;
113: 5293–5298.
69.
TangXLiuYXiaoQ, et al.
Pathological cyclic strain promotes proliferation of vascular smooth muscle cells via the ACTH/ERK/STAT3 pathway.J Cell Biochem2018;
119: 8260–8270.
70.
Li W, Febbraio M, Reddy SPet al.
CD36 participates in a signaling pathway that regulates ROS formation in murine VSMCs.J Clin Investig2010;
120: 3996–4006.
71.
JuanSHLeeTSTsengKW, et al.
Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice. Circulation2001;
104: 1519–1525.
72.
YueHFebbraioMKlenoticPA, et al.
CD36 enhances vascular smooth muscle cell proliferation and development of neointimal hyperplasia.Arterioscler Thromb Vasc Biol2019;
39: 263–275.
73.
KuschATkachukSTkachukN, et al.
The tight junction protein ZO-2 mediates proliferation of vascular smooth muscle cells via regulation of Stat1.Cardiovasc Res2009;
83: 115–122.
74.
Guo F, Zarella C and Wagner WD.
STAT4 and the proliferation of artery smooth muscle cells in atherosclerosis. Exp Mol Pathol2006;
81: 15–22.
75.
LvLZhangJHuangX, et al.
Lentivirus-mediated RNA interference targeting STAT4 inhibits the proliferation of vascular smooth muscle cells.Arch Med Res2008;
39: 582–589.
76.
BucherFLeeJShinS, et al.
Interleukin-5 suppresses vascular endothelial growth factor-induced angiogenesis through STAT5 signaling.Cytokine2018;
110: 397–403.
77.
BaettaRSomaMDe-FrajaC, et al.
Upregulation and activation of Stat6 precede vascular smooth muscle cell proliferation in carotid artery injury model.Arterioscler Thromb Vasc Biol2000;
20: 931–939.
78.
Quelle FW, Shimoda K, Thierfelder Wet al.
Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cellul Biol1995;
15: 3336–3343.
79.
Kaplan MH, Daniel C, Schindler U,et al.
Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression. Mol Cellul Biol1998;
18: 1996–2003.
